Pharmaceuticals

Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "Sanyou" hereafter) and Sinorda Biomedicine (referred to as " Sinorda " hereafter) have officially signed a strategic cooperation agreement to advance the innovative bispecific antibody drug pro...

2023-08-22 20:00 1616

CARsgen Announced 2023 Interim Results

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results. Business Highlights * Collaboration agr...

2023-08-22 19:30 3103

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

SUZHOU, China, Aug. 22, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 180 patients for the Phase...

2023-08-22 17:13 1099

Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model

SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- GemPharmatech is proud to announce the launch of NeoMab™, our independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation. NeoMab™ is specifically designed to meet the burgeoning therapeutic antib...

2023-08-22 08:59 1281

CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer

The investigational monoclonal antibody becomes the first to target Mucin 1 (MUC1) and receive this designation. PYEONGTAEK, South Korea, Aug. 21, 2023 /PRNewswire/ -- CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immun...

2023-08-21 20:00 1616

Hummingbird Bioscience to Present Poster on HMBD-001 Combination Strategy for Squamous Non-Small Cell Lung Cancer at World Conference on Lung Cancer 2023

HOUSTON and SINGAPORE, Aug. 21, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at the IASLC 2023 World Conference ...

2023-08-21 17:58 1280

Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy

SHANGHAI, Aug. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for Nefecon® from its partner Calliditas Therapeutics AB ...

2023-08-21 08:20 1677

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

NEW YORK, Aug. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination fromAugust 19, 2023 to September 19, 2023, for each public share that...

2023-08-19 04:30 5012

3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling

REYKJAVIK, Iceland and BERLIN, Aug. 18, 2023 /PRNewswire/ -- Reykjavik-based drug discovery company, 3Z, andGermany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging advanced AI modelling techniques, the ...

2023-08-18 22:45 2622

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

HONG KONG, Aug. 18, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso. The Phase III trial will e...

2023-08-18 20:00 5897

Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study

* IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-life * IMG-007 has demonstrated a favorable safety profile, consistent with a silenced ADCC function via bioengineering * IMG-007 is being evaluated in two global proof-of-concept trials  SAN DIEGO,...

2023-08-18 19:00 4468

JinMed (NASDAQ: ZJYL) Rings the Nasdaq Stock Market Closing Bell on August 17

CHANGZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Jin Medical International Limited ("the Company" or "JinMed") (NASDAQ: ZJYL), the world's leading provider of rehabilitation equipment, rang the bell at the New York Stock Exchange by its Chairman and CEOWang Erqi on August 17, to celebrate the Com...

2023-08-18 11:36 3989

QiLu Pharmaceutical's Iruplinalkib Phase III INSPIRE Study Researched Primary Endpoint and was Selected for 2023 WCLC Oral Presentation

JINAN, China, Aug. 18, 2023 /PRNewswire/ -- August 16, 2023, at the 2023 World Conference on Lung Cancer (WCLC), the complete list of selected abstracts was announced, among which QiLu Pharmaceutical's iruplinalkib phase III clinical trial (INSPIRE) results were chosen for oral presentation at th...

2023-08-18 09:50 2217

Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements.

* Analyzed the FDA FAERS data…to compare the thrombotic AEs of Hemlibra vs. FVIII replacements. YONGIN, South Korea, Aug. 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced on August 17, 2023 that it has presented the results of analyzing and...

2023-08-18 08:58 2015

Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet

SHANGHAI, Aug. 18, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced the publication inThe Lancet of the full data from the NeflgArd Phase 3 trial with Nefecon® in...

2023-08-18 08:41 1928

Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy

WUHAN, China and SAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused byND1 ...

2023-08-17 21:00 1195

Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis

SHANGHAI, HANGZHOU, China and WILMINGTON, Del., Aug. 17, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, today announced the successful enrollment of the first patient in the phase 3 clinical study for MH004 Cream targeting mild to moderate a...

2023-08-17 19:00 4090

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

* Significant progress made year-to-date on key clinical assets: ‐         Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐         Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including pat...

2023-08-17 18:00 4074

2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with Sunvozertinib

* A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctDNA) testing in detecting EGFR exon 20 insertion (Exon20ins) mutations. * Both tumor tissue-based and plasma ctDNA testing can be used to identify patients who may benefit from treatment with su...

2023-08-17 17:10 1912

Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...

2023-08-17 08:00 2809
1 ... 40414243444546 ... 291